These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer. Gerard SK; Dam HQ Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947 [No Abstract] [Full Text] [Related]
5. What is the best strategy to treat and study patients after near-total thyroidectomy? Sarmiento AJ; Sarmiento FM; Sarmiento AH J Nucl Med; 2001 Mar; 42(3):531-3. PubMed ID: 11337535 [No Abstract] [Full Text] [Related]
6. Do we read carefully? Medvedec M Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):475-6. PubMed ID: 12634977 [No Abstract] [Full Text] [Related]
7. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552 [TBL] [Abstract][Full Text] [Related]
8. Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning". Kalinyak JE; McDougall IR Nucl Med Commun; 2004 Sep; 25(9):883-9. PubMed ID: 15319592 [No Abstract] [Full Text] [Related]
9. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Dam HQ; Kim SM; Lin HC; Intenzo CM Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323 [TBL] [Abstract][Full Text] [Related]
10. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909 [TBL] [Abstract][Full Text] [Related]
11. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. Morris LF; Waxman AD; Braunstein GD J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771 [TBL] [Abstract][Full Text] [Related]
13. 123Imaging in the follow-up of differentiated thyroid cancer. Violet J; Nutting C; Plowman PN; Britton KE Clin Oncol (R Coll Radiol); 2001; 13(4):313-4. PubMed ID: 11554638 [No Abstract] [Full Text] [Related]
14. 123 I as a diagnostic tracer in the management of thyroid cancer. Kalinyak JE Nucl Med Commun; 2002 Jun; 23(6):509-11. PubMed ID: 12029204 [No Abstract] [Full Text] [Related]
15. [Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out]. Koch W; Knesewitsch P; Tatsch K; Hahn K Nuklearmedizin; 2003 Feb; 42(1):10-4. PubMed ID: 12601448 [TBL] [Abstract][Full Text] [Related]
20. Scintigraphic control of radioiodine 131-I distribution following administration of therapeutic dose for a differentiated cancer of the thyroid gland. Röhling S; Nĕmec J; Zamrazil V; Pohunková D; Jezek V Czech Med; 1983; 6(2):125-6. PubMed ID: 6409563 [No Abstract] [Full Text] [Related] [Next] [New Search]